PortfoliosLab logo
ABVC Biopharma Inc (ABVC)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00091F1066

IPO Date

Oct 11, 2017

Highlights

Market Cap

$17.67M

EPS (TTM)

-$0.42

Total Revenue (TTM)

$510.35K

Gross Profit (TTM)

$507.82K

EBITDA (TTM)

-$709.36K

Year Range

$0.40 - $1.40

Target Price

$2.02

Short %

1.96%

Short Ratio

0.45

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
ABVC vs. QQQ
Popular comparisons:

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ABVC Biopharma Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%December2025FebruaryMarchAprilMay
-99.61%
108.89%
ABVC (ABVC Biopharma Inc)
Benchmark (^GSPC)

Returns By Period

ABVC Biopharma Inc (ABVC) returned 123.73% year-to-date (YTD) and 18.92% over the past 12 months.


ABVC

YTD

123.73%

1M

47.52%

6M

143.36%

1Y

18.92%

5Y*

-47.35%

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.70%

1M

13.67%

6M

-5.18%

1Y

9.18%

5Y*

14.14%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of ABVC, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-12.37%33.48%53.60%-0.00%24.53%123.73%
202431.03%-20.39%8.26%-4.58%-36.47%-2.53%0.67%-13.33%1.20%1.11%-23.30%11.32%-49.14%
202315.44%-7.97%-3.61%6.25%0.01%-23.61%-52.07%-47.39%-20.61%3.85%16.67%-7.94%-81.44%
2022-26.25%-0.80%10.08%-12.45%-17.15%-46.46%-38.68%55.38%-12.87%-17.05%1.19%-15.39%-81.56%
2021-1.96%-12.00%2.27%0.00%22.22%-8.18%-2.18%-41.30%-20.34%9.96%19.69%11.51%-33.53%
2020-33.64%-0.00%-15.52%30.61%-6.25%0.00%31.67%1.27%-0.00%-2.50%7.69%21.43%16.70%
2019-25.00%-3.33%3.45%-16.67%-4.44%-39.53%-15.38%-25.73%10.16%-41.11%25.47%-34.29%-87.86%
20180.00%5.26%-17.50%-3.03%25.00%5.26%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ABVC is 63, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ABVC is 6363
Overall Rank
The Sharpe Ratio Rank of ABVC is 6060
Sharpe Ratio Rank
The Sortino Ratio Rank of ABVC is 6868
Sortino Ratio Rank
The Omega Ratio Rank of ABVC is 6565
Omega Ratio Rank
The Calmar Ratio Rank of ABVC is 6262
Calmar Ratio Rank
The Martin Ratio Rank of ABVC is 6060
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ABVC Biopharma Inc (ABVC) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current ABVC Biopharma Inc Sharpe ratio is 0.20. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of ABVC Biopharma Inc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
0.20
0.48
ABVC (ABVC Biopharma Inc)
Benchmark (^GSPC)

Dividends

Dividend History


ABVC Biopharma Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-99.65%
-7.82%
ABVC (ABVC Biopharma Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ABVC Biopharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ABVC Biopharma Inc was 99.89%, occurring on Feb 13, 2025. The portfolio has not yet recovered.

The current ABVC Biopharma Inc drawdown is 99.65%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.89%Jan 3, 20191377Feb 13, 2025
-25%Sep 12, 20183Dec 18, 20183Dec 31, 20186
-0.53%May 16, 20181May 16, 20181May 29, 20182

Volatility

Volatility Chart

The current ABVC Biopharma Inc volatility is 28.93%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%December2025FebruaryMarchAprilMay
28.93%
11.21%
ABVC (ABVC Biopharma Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ABVC Biopharma Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of ABVC Biopharma Inc, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -1,945.3%.


-0.80-0.60-0.40-0.200.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJuly
-0.02
-0.04
Actual
Estimate

Valuation

The Valuation section provides an overview of how ABVC Biopharma Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ABVC relative to other companies in the Biotechnology industry. Currently, ABVC has a P/S ratio of 34.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ABVC in comparison with other companies in the Biotechnology industry. Currently, ABVC has a P/B value of 13.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items